Related Experiment Video
Updated: Aug 31, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study
Seyed Saman Talebi1, Mehran Ghasemi2, Maryam Etminani-Esfahani3
1Department of Internal Medicine, School of Medicine, Shahid Beheshti Medical Educational Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Background:
The present single-center clinical trial was designed to evaluate the potential benefits of L-carnitine supplementation in patients with COVID-19 disease.
Methods And Patients:
The study was conducted on 75 patients with mild-to-moderate COVID-19 hospitalized in Shahid Beheshti Hospital-Hamadan, IRAN. The participants were randomly divided into intervention (n = 32) and control groups (n = 43). The control group received their standard hospital treatment only. In addition to standard medications, the intervention group received 3000 mg oral L-carnitine daily in three divided doses for five days. The blood samples were collected and para-clinical parameters were measured at the beginning and end of the treatment. Clinical outcomes were also recorded, and data were analyzed using χ2 and t-tests.
Results:
Higher means of O2 saturation were observed in the intervention rather than in the control group. Mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were significantly lower in the intervention group. Furthermore, mean alkaline phosphatase (ALP) activity and lactate dehydrogenase (LDH) were lower in the intervention group. Also, lower mean serum creatine phosphokinase (CPK) was observed in the intervention group. No significant differences were observed in terms of clinical symptoms; however, six patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived.
Conclusion:
Taken together, L-carnitine can be considered as a drug supplement in patients with COVID-19.
More Related Videos
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
COPD: Management Using Bronchodilators and Corticosteroids
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...